CARGO Therapeutics (CRGX) Competitors

CARGO Therapeutics (NASDAQ:CRGX) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Is CRGX or ZYME more profitable?

CARGO Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -59.96%. Zymeworks' return on equity of -21.59% beat CARGO Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-43.21%	-37.26%
Zymeworks	-59.96%	-21.59%	-16.52%

Which has more volatility & risk, CRGX or ZYME?

CARGO Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Does the media favor CRGX or ZYME?

In the previous week, Zymeworks had 1 more articles in the media than CARGO Therapeutics. MarketBeat recorded 3 mentions for Zymeworks and 2 mentions for CARGO Therapeutics. CARGO Therapeutics' average media sentiment score of 0.62 beat Zymeworks' score of 0.38 indicating that CARGO Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CARGO Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has better earnings and valuation, CRGX or ZYME?

Zymeworks has higher revenue and earnings than CARGO Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CARGO Therapeutics	N/A	N/A	-$167.50M	-$4.64	-0.96
Zymeworks	$76.30M	14.09	-$122.69M	-$0.97	-14.74

Do analysts rate CRGX or ZYME?

CARGO Therapeutics presently has a consensus target price of $15.40, indicating a potential upside of 245.29%. Given CARGO Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe CARGO Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Zymeworks	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals and insiders believe in CRGX or ZYME?

93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 2.9% of CARGO Therapeutics shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

CARGO Therapeutics and Zymeworks tied by winning 7 of the 14 factors compared between the two stocks.